论文信息 - Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) - 字舞流文

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)

C. Schumann | R. Beckman | J. Tseng | M. Dediu | J. Mendell | Xiaoping Jin | J. Pawel | B. Moritz | C. Copigneaux | Wenqin Feng